Skip to main content

Michael R Abern, MD

Associate Professor of Surgery
Office: 40 Duke Medicine Circle, DUMC Box 3707, Durham, NC 27710
Campus Mail: DUMC 200 Trent Drive, DUMC Box 2804, Durham, NC 27710

Education and Training

  • Urologic Oncology Fellow, Surgery, Duke University School of Medicine, 2011 - 2013
  • Urology Resident, Surgery, Rush University Medical Center, 2006 - 2011
  • M.D., Rush University, Medical College, 2006
  • B.S., University of Illinois, 1996

Publications

Dobbs, R. W., D. T. Greenwald, H. Wadhwa, V. L. Freeman, and M. R. Abern. “Is prostate cancer stage migration continuing for black men in the PSA era?” Prostate Cancer Prostatic Dis 20, no. 2 (June 2017): 210–15. https://doi.org/10.1038/pcan.2016.68.

Full Text

Sharif, Asma, Neha R. Malhotra, Andres M. Acosta, Andre A. Kajdacsy-Balla, Maarten Bosland, Grace Guzman, Gail S. Prins, and Michael R. Abern. “The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?” Prostate 77, no. 8 (June 2017): 824–28. https://doi.org/10.1002/pros.23322.

Full Text

Wilson, Nathaniel, Dimitri Papagiannopoulos, Nicholas O’Block, Michael Abern, Lester Raff, Christopher Coogan, and Kalyan Latchamsetty. “MP11-15 PREDICTORS OF FLUOROQUINOLONE RESISTANCE IN THE RECTAL VAULT OF MEN UNDERGOING PROSTATE BIOPSY.” In Journal of Urology, Vol. 197. Ovid Technologies (Wolters Kluwer Health), 2017. https://doi.org/10.1016/j.juro.2017.02.416.

Full Text

Tsivian, Matvey, Rajan T. Gupta, Efrat Tsivian, Peter Qi, Melissa H. Mendez, Michael R. Abern, Kae Jack Tay, and Thomas J. Polascik. “Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology.” Int J Urol 24, no. 2 (February 2017): 137–43. https://doi.org/10.1111/iju.13251.

Full Text

Fantony, Joseph J., Thomas A. Longo, Ajay Gopalakrishna, Richmond Owusu, Raymond S. Lance, Wen-Chi Foo, Brant A. Inman, and Michael R. Abern. “Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.” Cancer Biomark 18, no. 4 (2017): 381–87. https://doi.org/10.3233/CBM-160261.

Full Text

Wadhwa, H., M. K. Terris, W. J. Aronson, C. J. Kane, C. L. Amling, M. R. Cooperberg, S. J. Freedland, and M. R. Abern. “Long-term oncological outcomes of apical positive surgical margins at radical prostatectomy in the Shared Equal Access Regional Cancer Hospital cohort.” Prostate Cancer Prostatic Dis 19, no. 4 (December 2016): 423–28. https://doi.org/10.1038/pcan.2016.45.

Full Text

Abhyankar, N., O. Shoshany, M. Kathrins, M. Abern, and C. Niederberger. “A safety study of clomiphene citrate; evaluating its effects on PSA, hemoglobin and estradiol.” In Fertility and Sterility, 106:e238–39. Elsevier BV, 2016. https://doi.org/10.1016/j.fertnstert.2016.07.686.

Full Text

Longo, Thomas, Ajay Gopalakrishna, Joseph Fantony, Richmond Owusu, Raymond Lance, Wen-Chi Foo, Brant Inman, and Michael Abern. “MP01-09 CAN A GENE METHYLATION ASSAY IMPROVE THE PERFORMANCE OF CYTOLOGY?” In Journal of Urology, Vol. 195. Ovid Technologies (Wolters Kluwer Health), 2016. https://doi.org/10.1016/j.juro.2016.02.1839.

Full Text

Abhyankar, Nikita, Kent Hoskins, Michael Abern, and Gregory Calip. “PD09-08 SHOULD A MAN WITH A HISTORY OF BREAST CANCER BE SCREENED FOR PROSTATE CANCER?” In Journal of Urology, Vol. 195. Ovid Technologies (Wolters Kluwer Health), 2016. https://doi.org/10.1016/j.juro.2016.02.2903.

Full Text

Pages